Skye Bioscience, Inc., a pharmaceutical company developing a synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization (CMO) for its Phase 2 clinical trial material.   NextPharma is a European pharmaceutical contract development and manufacturing organization that supplies products globally from its nine sites. The company provides services that range from pharmaceutical development, clinical supplies, scale-up and process validation...